Document is current
Any future updates will be listed below
-
Authors
Baggio, Diva
Hawkes, Eliza A. https://orcid.org/0000-0002-0376-2559
Simonsen, Mikkel Runason https://orcid.org/0009-0001-1119-4782
El-Galaly, Tarec Christoffer https://orcid.org/0000-0002-4406-380X
- License Information
-
More Information
Article History
Received: 24 August 2025
Revised: 17 October 2025
Accepted: 11 November 2025
First Online: 19 November 2025
Competing interests
: DB: No COIs. EAH: EAH has received research funding from Bristol Myers Squibb/Celgene, Merck KgA, AstraZeneca, TG therapeutics and F. Hoffmann-La Roche (all paid to institution); has acted as a consultant/advisor for F. Hoffmann-La Roche, Antengene, Bristol Myers Squibb, AstraZeneca, Novartis, Merck Sharpe Dohme, Specialised therapeutics, Sobi, Regeneron, Gilead and Abbvie; has acted as a speaker for Roche, AstraZeneca, Janssen, Regeneron, Abbvie and Genmab and received travel expenses from Astra Zeneca and Abbvie. MRS: No COIs. TCEG: No COIs. The views expressed in this editorial are those of the authors and do not necessarily reflect the views or positions of any entities the authors are affiliated to or collaborate with.
: The views expressed in this editorial are those of the authors and do not necessarily reflect the views or positions of any entities the authors are affiliated to or collaborate with.
